Toll-like receptor-agonists in the treatment of skin cancer: History, current developments and future prospects

Handbook of Experimental Pharmacology

Volumn 183, Issue , 2008, Pages 201-220

  Wenzel, Joerg ^a   Tormo, Damia ^a   Tüting, Thomas ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; IMMUNOLOGICAL ADJUVANT; OLIGONUCLEOTIDE; RNA; TOLL LIKE RECEPTOR;

ANIMAL; CYTOLOGY; DRUG POTENTIATION; FUNCTIONS OF THE SKIN AND ITS APPENDAGES; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; REVIEW; SKIN; SKIN TUMOR;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; DNA; HUMANS; IMMUNOTHERAPY; OLIGONUCLEOTIDES; RNA; SKIN; SKIN NEOPLASMS; SKIN PHYSIOLOGY; TOLL-LIKE RECEPTORS;

EID: 39349110547     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-540-72167-3_10     Document Type: Article

References (100)

1. Ahmed I, Berth-Jones J (2000) Imiquimod: A novel treatment for lentigo maligna. Br J Dermatol 143: 843-845
2. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738
3. Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini JC, Romero P, Leyvraz S, Rufer N, Speiser DE (2006) New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 177: 1670-1678
4. Baron S, Bogomolova NN, Billiau A, Levy HB, Buckler CE, Stern R, Naylor R (1969) Induction of interferon by preparations of synthetic single-stranded RNA. Proc Natl Acad Sci USA 64: 67-74
5. Bart RS, Kopf AW, Silagi S (1971) Inhibition of the growth of murine malignant melanoma by polyinosinic-polycytidylic acid. J Invest Dermatol 56: 33-38
6. Beutner KR, Tyring SK, Trofatter KF, Jr, Douglas JM, Jr, Spruance S, Owens ML, Fox TL, Hougham AJ, Schmitt KA (1998) Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 42: 789-794
7. Black AP, Ogg GS (2003) The role of p53 in the immunobiology of cutaneous squamous cell carcinoma. Clin Exp Immunol 132: 379-384
8. Boukamp P (2005) Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 26: 1657-1667
9. Bourquin C, Schreiber S, Beck S, Hartmann G, Endres S (2006) Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. Int J Cancer 118: 2790-2795
10. Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13: 1-27
11. Chaudhry UI, Kingham TP, Plitas G, Katz SC, Raab JR, DeMatteo RP (2006) Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth. Cancer Res 66: 10497-10504
12. Chee DO, Bodurtha AJ (1974) Facilitation and inhibition of b16 melanoma by BCG in vivo and by lymphoid cells from bcg-treated mice in vitro. Int J Cancer 14: 137-143
13. Chin L, Garraway LA, Fisher DE (2006) Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 20: 2149-2182
14. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV (1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186: 1623-1631
15. Clark WH, Jr, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 20(81): 1893-1904
16. Clemente CG, Mihm MC, Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77: 1303-1310
17. Coley WB (1991) The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 3-11
18. Craft N, Bruhn KW, Nguyen BD, Prins R, Lin JW, Liau LM, Miller JF (2005) The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol 175: 1983-1990
19. Davila E, Celis E (2000) Repeated administration of cytosine-phosphorothiolated guaninecontaining oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 165: 539-547
20. Davila E, Kennedy R, Celis E (2003) Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 63: 3281-3288
21. De CE, Nuwer MR, Merigan TC (1970) The role of interferon in the protective effect of a synthetic double-strandedpolyribonucleotide against intranasal vesicular stomatitis virus challenge in mice. J Clin Invest 49: 1565-1577
22. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD (2005) A critical function for type I interferons in cancer immunoediting. Nat Immunol 6: 722-729
23. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148
24. Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348: 1681-1691
25. Field AK, Tytell AA, Lampson GP, Hilleman MR (1967) Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci USA 58: 1004-1010
26. Flacher V, Bouschbacher M, Verronese E, Massacrier C, Sisirak V, Berthier-Vergnes O, de Saint- Vis B, Caux C, Dezutter-Dambuyant C, Lebecque S, Valladeau J (2006) Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J Immunol 177: 7959-7967
27. Garbi N, Arnold B, Gordon S, Hammerling GJ, Ganss R (2004) CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol 172: 5861-5869
28. Gelboin HV, Levy HB (1970) Polyinosinic-polycytidylic acid inhibits chemically induced tumorigenesis in mouse skin. Science 167: 205-207
29. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC (2001) Regulation of cutaneous malignancy by gammadelta T cells. Science 19(294): 605-609
30. Hadley G, Derry S, Moore RA (2006) Imiquimod for actinic keratosis: Systematic review and meta-analysis. J Invest Dermatol 126: 1251-1255
31. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM (2000) Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164: 1617-1624
32. Hartmann G, Weiner GJ, Krieg AM (1999) CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 96: 9305-9310
33. Hawkins MJ, Levin M, Borden EC (1985) An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. J Biol Response Mod 4: 664-668
34. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B, Krug A, Rothenfusser S, Endres S, Hartmann G (2002) Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 169: 3892-3899
35. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88- dependent signaling pathway. Nat Immunol 3: 196-200
36. Hober D, Ajram L, Chehadeh W, Lazrek M, Goffard A, Dewilde A, Wattre P (2005) Mechanisms of imiquimod indirect antiviral activity. Ann Biol Clin (Paris) 63: 155-163
37. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, Hartmann G (2006) 5-Triphosphate RNA is the ligand for RIG-I. Science 314: 994-997
38. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de FA, Endres S, Hartmann G (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11: 263-270
39. Huebner RJ, Rowe WP, Schatten WE, Smith RR, Thomas LB (1956) Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9: 1211-1218
40. Jacobs S, Grussendorf-Conen EI, Rosener I, Rubben A (2004) Molecular analysis of the effect of topical imiquimod treatment of HPV 2/27/57-induced common warts. Skin Pharmacol Physiol 17: 258-266
41. Jakob T,Walker PS, Krieg AM, Udey MC, Vogel JC (1998) Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 161: 3042-3049
42. Janeway CA, Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197-216. Epub 2001 Oct 4: 197-216
43. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa, Matsuura Y, Fujita T, Akira S (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-105
44. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ (2001) NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 167: 5247-5253
45. Kochenderfer JN, Chien CD, Simpson JL, Gress RE (2006) Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses. J Immunol 177: 8860-8873
46. Kreider JW, Benjamin SA (1972) Tumor immunity and the mechanism of polyinosinicpolycytidylic acid inhibition of tumor growth. J Natl Cancer Inst 49: 1303-1310
47. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549
48. Kunikata N, Sano K, Honda M, Ishii K, Matsunaga J, Okuyama R, Takahashi K, Watanabe H, Tamura G, Tagami H, Terui T (2004) Peritumoral CpG oligodeoxynucleotide treatment inhibits tumor growth and metastasis of B16F10 melanoma cells. J Invest Dermatol 123: 395-402
49. Lebre MC, van der Aar AM, van Baarsen L, van Capel TM, Schuitemaker JH, Kapsenberg ML, de Jong EC (2006) Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 127: 331-341
50. Levine AS, Sivulich M, Wiernik PH, Levy HB (1979) Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. Cancer Res 39: 1645-1650
51. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K (1997) CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants. Eur J Immunol 27: 2340-2344
52. Lysa B, Tartler U, Wolf R, Arenberger P, Benninghoff B, Ruzicka T, Hengge UR, Walz M (2004) Gene expression in actinic keratoses: Pharmacological modulation by imiquimod. Br J Dermatol 151: 1150-1159
53. Medzhitov R, Janeway CA, Jr (2002) Decoding the patterns of self and nonself by the innate immune system. Science 296: 298-300
54. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397
55. Memon AA, Tomenson JA, Bothwell J, Friedmann PS (2000) Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 142: 1154-1159
56. Michalopoulos P, Yawalkar N, Bronnimann M, Kappeler A, Braathen LR (2004) Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol 151: 903-906
57. Miconnet I, Koenig S, Speiser D, Krieg A, Guillaume P, Cerottini JC, Romero P (2002) CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 168: 1212-1218
58. Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, Krieg AM, Whisnant JK (2004) CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 64: 5074-5077
59. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA (1999) Imiquimod applied topically: A novel immune response modifier and new class of drug. Int J Immunopharmacol 21: 1-14
60. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6: 769-776
61. Nordlund JJ, Wolff SM, Levy HB (1970) Inhibition of biologic activity of poly I:poly C by human plasma. Proc Soc Exp Biol Med 133: 439-444
62. Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M (2004) Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 173: 3051-3061
63. Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+ CD25+ T cellmediated suppression by dendritic cells. Science 299: 1033-1036
64. Pashenkov M, Goess G, Wagner C, Hormann M, Jandl T, Moser A, Britten CM, Smolle J, Koller S, Mauch C, Tantcheva-Poor I, Grabbe S, Loquai C, Esser S, Franckson T, Schneeberger A, Haarmann C, Krieg AM, Stingl G, Wagner SN (2006) Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 20(24): 5716-5724
65. Pilon-Thomas S, Li W, Briggs JJ, Djeu J, Mule JJ, Riker AI (2006) Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J Immunother 29: 381-387
66. Purnell DM, Kreider JW, Bartlett GL (1975) Evaluation of antitumor activity of Bordetella pertussis in two murine tumor models. J Natl Cancer Inst 55: 123-128
67. Rajpar SF, Marsden JR (2006) Imiquimod in the treatment of lentigo maligna. Br J Dermatol 155: 653-656
68. Robbins PF, el-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA (1996) A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183: 1185-1192
69. Robinson RA, DeVita VT, Levy HB, Baron S, Hubbard SP, Levine AS (1976) A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patients with leukemia or solid tumors. J Natl Cancer Inst 57: 599-602
70. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E (1997) Immunostimulatory DNA sequences function as T helper- 1-promoting adjuvants. Nat Med 3: 849-854
71. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman GJ, Lotz M, Carson DA, Raz E (1996) Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 19(273): 352-354
72. Sauder DN (2000) Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 43: S6-11
73. Schlee M, Hornung V, Hartmann G (2006) siRNA and isRNA: Two edges of one sword. Mol Ther 14: 463-470
74. Schon MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC, Gollnick H, Schon M (2004) Death receptor-independent apoptosis in malignant melanoma induced by the smallmolecule immune response modifier imiquimod. J Invest Dermatol 122: 1266-1276
75. Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, Chen Q, Parente P, Jefford M, Masterman KA, Caron D, Chen W, Maraskovsky E, Cebon J (2004) The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 4:9.: 9
76. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111
77. Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW, Wagner H (1998) Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 28: 2045-2054
78. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115: 739-746
79. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G (2007) Tumoricidal activity of TLR7/8- activated inflammatory dendritic cells. J Exp Med 204: 1441-1451
80. Takeshita F, Leifer CA, Gursel I, Ishii KJ, Takeshita S, Gursel M, Klinman DM (2001) Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 167: 3555-3558
81. Tang DC, DeVit M, Johnston SA (1992) Genetic immunization is a simple method for eliciting an immune response. Nature 356: 152-154
82. Todd RW, Steele JC, Etherington I, Luesley DM (2004) Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for highgrade vulval intraepithelial neoplasia. Gynecol Oncol 92: 167-174
83. Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T (1984) Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 72: 955-962
84. Tormo D, Ferrer A, Bosch P, Gaffal E, Basner-Tschakarjan E, Wenzel J, Tting T (2006a) Therapeutic efficacy of antigen-specific vaccination and Toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res 66: 5427-5435
85. Tormo D, Ferrer A, Gaffal E,Wenzel J, Basner-Tschakarjan E, Steitz J, Heukamp LC, Gutgemann I, Buettner R, Malumbres M, Barbacid M, Merlino G, Tting T (2006b) Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factortransgenic mice carrying an oncogenic CDK4 mutation. Am J Pathol 169: 665-672
86. Tyring S (2001) Imiquimod applied topically: A novel immune response modifier. Skin Therapy Lett 6[6]
87. Ulmer JB, Sadoff JC, Liu MA (1996) DNA vaccines. Curr Opin Immunol 8: 531-536
88. Urosevic M, Dummer R, Conrad C, Beyeler M, Laine E, Burg G, Gilliet M (2005) Diseaseindependent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 97[15]: 1903
89. Vabulas RM, Pircher H, Lipford GB, Hacker H, Wagner H (2000) CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J Immunol 164: 2372-2378
90. Wang RF (2006) Regulatory T cells and Toll-like receptors in cancer therapy. Cancer Res 66: 4987-4990
91. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM (1997) Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 94: 10833-10837
92. Wenzel J, Uerlich M, Haller O, Bieber T, Tting T (2005a) Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J Cutan Pathol 32: 257-262
93. Wenzel J, Uerlich M,Worrenkamper E, Freutel S, Bieber T, Tting T (2005b) Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol 153: 1011-1015
94. Whitmore MM, DeVeer MJ, Edling A, Oates RK, Simons B, Lindner D, Williams BR (2004) Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 64: 5850-5860
95. Wolf IH, Cerroni L, Kodama K, Kerl H (2005) Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 141: 510-514
96. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De PE, Hankeln T, Meyer zum Buschenfelde KH, Beach D (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281-1284
97. Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T, Tokunaga T (1992) DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 36: 983-997
98. Yamamoto T, Yamamoto S, Kataoka T, Komuro K, Kohase M, Tokunaga T (1994) Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. Jpn J Cancer Res 85: 775-779
99. Youdim S (1976) Resistance to tumor growth mediated by Listeria monocytogenes. Destruction of experimental malignant melanoma by LM-activated peritoneal and lymphoid cells. J Immunol 116: 579-584
100. Zeleznick LD, Bhuyan BK (1969) Treatment of leukemic (L-1210) mice with double-stranded polyribonucleotides. Proc Soc Exp Biol Med 130: 126-128